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Abstract
Therapeutic intervention in inflammatory bowel diseases (IBDs) is often associated with adverse effects related to drug
distribution into non-diseased tissues, a situation which attracts a rational design of a targeted treatment confined to the
inflamed mucosa. Upon activation of immune cells, transferrin receptor (TfR) expression increases at their surface. Because
TfR is expressed in all cell types we hypothesized that its cell surface levels are regulated also in enterocytes. We, therefore,
compared TfR expression in healthy and inflamed human colonic mucosa, as well as healthy and inflamed colonic mucosa
of the DNBS-induced rat model. TfR expression was elevated in the colonic mucosa of IBD patients in both the basolateral
and apical membranes of the enterocytes. Increased TfR expression was also observed in colonocytes of the induced colitis
rats. To explore the underlying mechanism CaCo-2 cells were treated with various proinflammatory cytokines, which
increased both TfR expression and transferrin cellular uptake in a mechanism that did not involve hyper proliferation. These
findings were then exploited for the design of targetable carrier towards inflamed regions of the colon. Anti-TfR antibodies
were conjugated to nano-liposomes. As expected, iron-starved Caco-2 cells internalized anti-TfR immunoliposomes better
than controls. Ex vivo binding studies to inflamed mucosa showed that the anti-TfR immunoliposomes accumulated
significantly better in the mucosa of DNBS-induced rats than the accumulation of non-specific immunoliposomes. It is
concluded that targeting mucosal inflammation can be accomplished by nano-liposomes decorated with anti-TfR due to
inflammation-dependent, apical, elevated expression of the receptor.
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Introduction
Ulcerative colitis and Crohn’s disease, collectively termed
inflammatory bowel disease (IBD), are the two main chronic
relapsing inflammatory diseases of the intestines. While the former
is confined to the large bowel, the latter involves the entire gut.
The clinical presentation is largely dependent on the disease
location and may include diarrhea, abdominal pain, fever, bowel
obstruction and bloody stool. Typical complications associated
withCD includestrictures, abscesses, or fistulas [1,2]. The etiologies
of both ulcerative colitis and Crohn’s disease remain unclear and
are presumed to result from inherited and environmental factors
involving the immune system. Whether the immune system is
activated intrinsically (constitutive activation or failure of down-
regulatory mechanisms), or by a continuous, mucosal driven
stimulation is still unknown [3,4].
Despite significant progress in IBD therapy, in particular after
the introduction of biological drugs such as infliximab [5,6],
patients often suffer disease relapse associated with impairments in
their quality of life. This often necessitates a therapy with high
doses of anti-inflammatory drugs (steroids or nonsteroidal anti-
inflammatory drugs) [7,8], a regimen commonly accompanied by
severe adverse effects. It was postulated by us and others that
delivery of potent anti-inflammatory drugs in the closest proximity
possible to the inflamed mucosal tissues would improve drug
efficacy and reduce toxicity [9,10,11]. Still, a major drawback of
such colonic delivery systems was their lack of specificity to the
inflamed regions within the organ.
It has recently shown that drug enrichment in inflamed mucosa
can be accomplished with negatively charged liposomes. Low and
high molecular weight antioxidants that were delivered via anionic
liposomes to the inflamed mucosa of experimental colitis-induced
rats were more effective in attenuating the induced inflammation
compared with aqueous solutions of the enzymes [12]. This was
probably due to specific attachment of the negatively charged
liposomes to the inflamed regions, which led to a prolonged
residence time and a better uptake of the antioxidants into the
inflamed epithelium. It was also observed that while positively
charged liposomes exhibited enhanced adherence to both healthy
and normal intestinal mucosa, negatively charged liposomes
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epithelium of the rat colon [13]. A recent study, conducted in
our laboratory, provided evidence that transferrin (Tf) at the
luminal region of the inflamed colon, coupled with a typical low
luminal pH may be related to the mechanism underlying this
preferential adhesion [14]. This observation may also suggest a
role for mucosal transferrin receptor (TfR) in IBD. It has already
been reported that TfR levels are elevated in activated immune
cells, lymphocytes and macrophages [15,16]. In this study we
addressed the question whether TfR levels are subjected to similar
regulation in epithelial cells of the colon.
TfR internalizes the serum glycoprotein Tf (80 kDa) by endo-
cytosis [17]. Commonly, TfR is ubiquitously expressed at low
levels [18]. Its expression is elevated, however, in rapidly dividing
cells, including a variety of human cancers [19,20]. In addition to
its role in iron metabolism it was suggested that TfR may play a
role in cellular signaling and proliferation stimuli [21,22,23]. We
have already shown that the luminal aspect of the inflamed colon
epithelium of the rat was enriched with Tf [14], suggesting that the
increase in both mucosal Tf levels and TfR expression is associated
with the pathophysiology of IBD.
The objectives of the study were to: (a) measure the expression
levels of TfR in normal mucosa and in IBD; (b) elucidate the
relationship between typical IBD cytokines and mucosal TfR
expression and function in IBD and (c) examine the possibility to
preferentially target IBD mucosa with immuno-liposomes conju-
gated with anti-TfR.
Materials and Methods
Unless stated otherwise, all materials were purchased from
Sigma (St. Louis, MO, USA). Solvents were of analytical grade or
higher. Water was deionized and ultrafiltered by reverse osmosis
(Barnstead Nanopure, Waltham, MA). For detection of human
and rat TfR we used the monoclonal anti-TfR (H68.4, Abcam,
Cambridge, MA). Goat anti-mouse IgG Alexa FluorH 647 was
purchased from Invitrogen (Carlsbad, CA, USA). For detection of
human E-cadherin we used Mouse anti human E-cadherin BD
Transduction Laboratories (NJ USA). Rabbit anti-GRP78 (BiP)
antibody was obtained from Abcam (Cambridge, MA, USA).
Horseradish peroxidase (HRP) - conjugated secondary antibodies
were purchased from Jackson ImmunoResearch Laboratories
(Suffolk, UK) and Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Hydrogenated soybean phosphatidylcholine (HSPC),
phosphatidylglycerol (HSPG) and 1, 2-Dioleyl-sn-glycerol-3-phos-
phoethanolamine- N-carboxyfluorescein (PE-CF) were purchased
from Avanti Polar Lipids (Alabaster, AL, USA). NHS-PEG-DSPE
[3-(N-succinimidyloxyglutaryl) aminopropyl, polyethyleneglycol-
carbamyl distearoylphosphatidyl-ethanolamine] was obtained
from NOF Corporation (Tokyo, Japan). Elisa kit for rat TNFa
was obtained from R&D Systems, Inc. (MN, USA) and the mouse
Cytokine Screen ELISA from Quansys Biosciences (UT, USA).
Ethics statement
Inflamed and non-inflamed human colons were obtained as
slides of paraffin embedded from the Department of Surgery,
Hadassah - Hebrew University Medical Center, Mount Scopus.
This part of the study was approved by the Independent Ethical
Committee (IEC, Helsinki Committee)-Protocol # HMO-0512-
08. Adult patients operated on for inflammatory bowel disease
were offered participation in the trial. Eligible patients signed an
IEC-approved consent form.
All animal studies were conducted in accord with the Principles
of Laboratory Animal Care (NIH publication #85-23, revised1985)
under protocol no. MD-10603-4. The joint ethics committee
(IACUC) of the Hebrew University and Hadassah Medical Center
approved the study protocol for animal welfare. The Hebrew
University Animal Facility is an AAALAC international accredited
institute (#1285).
Rats, maintenance and euthanasia
Male Sabra rats (200–225 g), obtained from Harlan Laborato-
ries, Ein Kerem (Jerusalem, Israel) breeding farm, were kept under
constant environmental conditions (22uC, 12 h light/dark cycles)
and fed with standard laboratory chow and tap water. Anesthesia
was performed by an intraperitoneal injection of a mixture of
100 mg/kg body weight of ketamine (Ketaset, 0.1 g/mL, Fort
Dodge, IA, USA) and xylazine HCl (20 mg/mL). Euthanasia of
anesthetized rats was carried out by chest wall puncturing.
Induction of experimental colitis in the rat and
inflammation severity assessment
Twenty-four hours prior to colitis induction, the rats were
deprived of food, but allowed free access to water. Experimental
colitis was induced, under light anesthesia (isoflurane inhalation), by
a rectal slow (20 seconds) instillation of 30 mg of dinitrobenzensul-
fonic acid (DNBS) dissolved in 1 mL of 50% v/v ethanol through
a flexible, perforated foley catheter (0.3 mm outer diameter).
Immediately after the hapten administration the catheter was
removed and the rats were left in an inverted position for additional
40 seconds. Four days after colitis induction (maximal onset of
inflammation as identified in preliminary studies) the rats were
anesthetized as above, their abdomen was cut open and a 0.5 ml
blood was withdrawn from the portal vein for hematological
analysis (RBC, hematocrit and hemoglobin analyses). The colons
were removed and rinsed with normal saline. Inflammation severity
was scored (wet weight, dimensions, edema, hyperemia ulceration
areaand stool viscosity prior to the saline rinse)[12,24]. The control
(healthy) group was treated similarly with a normal saline solution
replacing the DNBS ethanolic solution. Homogenates of colon
tissues obtained from of inflamed or non-inflamed regions one or
four days after colitis induction were analyzed for TNFa by
commercial ELISA kit (Eli-pair, Diaclone, France).
TfR immunofluorescence analysis in rat colon mucosal
specimens and in human biopsies
Mucosal specimens from isolated rat colons (healthy or inflamed
regions) were rinsed with a 4% w/v aqueous sucrose solution and
fixated with 12% v/v formaldehyde in PBS. After a PBS rinse the
fixated tissues were preserved in a 20% w/v sucrose solution until
sectioning. Prior to sectioning the specimens were dehydrated
(ethanol and PBS). Sectioning (10–12 mm) was performed by
embedding in paraffin blocks and press-heating in 40 nM Tris/
1 Mm EDTA buffer pH 9, at 125uC for 2.45 minutes, followed by
27 min at 90uC. Nonspecific staining was blocked by 2% BSA in
PBS. Immunostaining of the fixed colonic specimens from the rat
or human biopsies was performed by their incubation (overnight,
4uC) with diluted (1:500) mouse anti-human TfR followed by
incubation (1 h, room temperature) with diluted (1:800) goat anti-
mouse IgG- Alexa 647. Nuclei were stained with 0.1 mg/ml of
Hoechst dye. Fluorescence was monitored by confocal microscopy
(Carl Zeiss, Germany).
Western analysis of TfR expression in the colonic mucosa
of the rat
Mucosal specimens from isolated rat colons from either DNBS-
induced or saline-treated rats were scraped with glass slides,
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(RIPA), shaken vigorously (15 min, 4uC) and centrifuged (10 min,
14,000 rpm, 4uC). The clear supernatant was collected and its
protein content was determination (Bradford). A volume equiva-
lent to 15 mg of protein was boiled in reduced Laemmli sample
buffer, analyzed by 12% SDS-PAGE and electrotransferred to a
nitrocellulose membrane. Membranes were blocked with 5% non-
fat milk in PBS containing 0.05% Tween 20 (PBST) for 1 hour at
room temperature and stained with mouse anti human TfR. HRP-
conjugated goat anti mouse was used as a secondary antibody.
Rabbit anti BiP was used as loading control, followed by HRP-
conjugated goat anti rabbit. Proteins were visualized by chemical
luminescence (EZ-ECL, Biological Industries, Israel).
Preparation of cytokine rich medium (CRM)
Male C57BL/6 mice (20 g) or male Sabra rats (250 g) were
sacrificed, their spleen was removed immediately into 10 ml of
PBS (RT) pounded and sieved through a cell strainer. The sieved
homogenate was centrifuged (5 min, 1,250 rpm) and red blood
cells were removed by incubation in lysis buffer (20 ml, 5 min,
RT). After centrifugation the supernatant was discarded and the
cells-containing pellet was resuspended immediately in 10 ml of
warm DMEM (no serum). 10610
6 cells/ml were plated in the
presence of 100 mg/ml of lipopolysaccharide (LPS) in a 96 wells
plate. After incubation (24 h, 37uC, 5% CO2) the content of each
well was aspirated, centrifuged (4,000 rpm, 20 min, 4uC), the
supernatants collected, and stored at 280uC until use for inflam-
mation induction. The cytokine content of the CRM was cha-
racterized by multi cytokines elisa (QUANSYS) according to the
manufacturer’s protocol. CRM was positive for IL-1a, IL-1b, IL-
3, IL-6, IL-10, Interferonc, TNFa, MIP-1 a, RANTES and
negative for IL-2, IL-4, IL-5, IL-12p70, IL-17, MCP-1, GM-CSF.
Preparation and characterization of negatively charged
fluorescently-tagged PEGylated immunoliposomes
Seven different liposomal formulations were prepared by the
ethanol injection method [14]. Lipid composition is specified in
Table 1. The formulations differed from each other by the
amount of antibodies (Ab) on their surface. All liposomes were
tagged fluorescently with 0.5 mole% of 18:1, 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine-N-(carboxyfluorescein). After di-
alysis against PBS, the liposomes were extruded stepwise with a
final extrusion through 100 nm pore polycarbonate filter and kept
in PBS at 4uC until use. The Ab was either mouse anti human TfR
(anti-TfR) or goat anti-mouse IgG (Anti IgG, served as non-
specific controls). The Ab was conjugated to the liposomes,
immediately after their preparation, with the aid of 3-(N-
succinimidyloxyglutaryl) aminopropyl, polyethyleneglycol-carbamyl
distearoylphosphatidyl-ethanolamine (NHS-PEG-DSPE) spacers,
which was added to the lipids before hydration preincorporated
into the liposomal formulation, at a ratio of 5 Mol% (Scheme S1).
The coupling reaction was terminated with 100 mM of TRIS
buffer.
Since the functional group for attaching the antibody (NHS
coupled to PEG-DSPE) is prone to hydrolysis prior to antibody
conjugation, we evaluated two pH conditions acidic (pH=5) and
neutral (pH=7.4) for liposome preparation. After liposome
extrusion, the antibody was coupled at pH value same as for
liposome fabrication (overnight, room temperature). Following
quenching of non reacting NHS groups with TRIS, non-bound
Ab was removed by ultracentrifugation (55,000 RPM, 2 h).
Ultracentrifugation did not affect liposome size (data not shown).
The pellet containing the immunoliposomes was resuspended in
PBS and kept at 4uC until use. After resuspension of the liposomal
pellet, an aliquot was removed and immediately boiled in reduced
Laemmli sample buffer. An equivalent portion of the supernatant,
which contains unconjugated Ab as well as non-precipitated
immunoliposomes, was also boiled in reduced Laemmli sample
buffer. Western blotting analysis for the presence of antibody
heavy and light chains indicated similar efficiency of antibody
coupling at either pH=7.4 or pH=5.0. We estimate the recovery
of the immunoliposomes by precipitation at approximately 50%,
as the antibody amount in the pellet (labeled as Pellet) or the
supernatant (labeled as Sup) was similar (figure 1A).
To further evaluate the effect of pH on the conjugation reaction,
we incorporated into the liposomes a carboxyfluorescein-tagged
lipid and used Alexa 647-tagged Ab. This double staining with
orthogonal fluorophores allowed a single step quantitation of the
conjugated Ab and the liposomes. Increasing amounts (1, 10 or
100 mg) of Alexa 647-labeled antibodies were incubated with the
carboxyfluorescein-tagged liposomes at pH=7.4 or pH=8.5.
Unbound Ab was removed by ultracentrifugation and the fluo-
rescence of either of the two fluorophores was determined in the
pelletandthesupernatant.The Alexa647 concentration-dependent
increase in the pellet’s fluorescence at l=647 nm, at two pH values
is shown in Figure 1B, indication on an Ab increase in the pellet.
Again, we observed a yield of ,50% regardless the antibody
Table 1. Materials used for the various liposomal formulations.
Liposomal Formulation
Name R No Ab Anti TfR 50 Anti TfR 5 Anti TfR 1 Anti IgG 100 Anti IgG 10 Anti IgG 1
Composition Mol% mM Mol% mM Mol% mM Mol% mM Mol% mM Mol% mM Mol% mM
HSPC 64.5 12.9 64.5 12.9 64.5 12.9 64.5 12.9 64.5 12.9 64.5 12.9 64.5 12.9
HSPG 30 6 30 6 30 6 30 6 30 6 30 6 30 6
NHS- PEG-DSPE 5 1 5 1 5 1 5 1 5 1 5 1 5 1
FC-PE 0.5 0.1 0.5 0.1 0.5 0.1 0.5 0.1 0.5 0.1 0.5 0.1 0.5 0.1
Ab amount (mg) -theoretical - 50 mg5 mg1 mg 100 mg1 0 mg1 mg
Abbreviations:
CRM: cytokine rich medium.
HSPC: Hydrogenated soy phosphatidylcholine.
HSPG: Hydrogenated soy phosphoglycerol (HSPG).
NHS-PEG-DSPE: 3-(N-succinimidyloxyglutaryl) aminopropyl, polyethyleneglycol-carbamyl distearoylphosphatidyl-ethanolamine.
FC-PE: 18:1, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(carboxyfluorescein).
doi:10.1371/journal.pone.0024202.t001
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of ultracentrifugation was better at pH 7.4 than 8.5 (70% and 55%,
respectively) (Figure 1D). Therefore all liposomal preparations
were conducted at pH=7.4. Similar results were obtained for the
mouse anti human TfR (Figures 1E and 1F). Based on the
ultracentrifugation recovery values, the conjugation efficacy was
estimated to be approximately 100%, as the amounts of Ab in both
liposomal pellet and supernatant were similar to the amounts of the
liposomes themselves in the corresponding fractions. This indicated
that the vast majority of Ab molecules in the supernatants were
conjugated to liposomes that failed to precipitate. Thus, the
ultracentrifugation step was the main limitation in the preparation
of the immunoliposomes.
Physical characterization of the immunoliposomes
Size distribution and zeta potential were analyzed after dilution
(1:100) with sodium nitrite 0.15 M by Zetasizer (3000 HS, Nano-
ZS, Malvern, UK). The size and zeta potential of the seven
formulations (Table 1) were similar, with an average size of
105.667 nm and a zeta potential of 214.163.3 mV. Fluorescence
level ofthe liposome was measured (Synergy HT,BioTek, VI, USA)
at lex=485 nm and lem=528 nm. Liposomes phospholipids
content was measured by determining their phospholipid phospho-
rus concentration as described elsewhere [25].
Liposomal antibody load quantification by Western blot
Twenty ml of the immunoliposomes were boiled in a reduced
Laemmli sample buffer and loaded onto 12% SDS-PAGE reso-
lution gel. Following electrotransfer to a nitrocellulose membrane,
Ab heavy and light chains were detected by HRP-conjugated
antibodies. Their amounts were assessed with the aid of a 4-points
calibration curve, prepared in a similar manner, using known
amounts of purified Ab.
Cell proliferation and TfR levels analysis by flow
cytometry
Low passage Caco-2 cells were purchased from the ATCC
(Manassas, VA). Cell proliferation was measured by carboxyfluor-
escein diacetate succinilimide ester (CFSE, Invitrogen, Merelbeke,
Belgium) dilution assay. In this assay, as the cell proliferates the
entrapped CFSE is diluted. Hence, proliferation is indicated by low
CFSE levels. Caco-2 cells, harvested by 2 mM of EDTA in PBS,
were resuspended in PBS containing 1% BSA and incubated
(7 min, 37uC) with 10 mm of CFSE, after which the cells were
washed and resuspended in a culture medium. The cells were
cultured for 24 h and the medium was replaced by a fresh one
containing the following recombinant human cytokines TNFa,
IL1b and IL-6 (Peprotech, Israel), separately, mixed together or
CRM and incubated for additional 24 h. Because CRM contained
Figure 1. Optimization of anti-TfR conjugation to the liposomes. (A) Identifying the optimal pH (5 or 7.4) for the imunoliposomal preparation
by Western blot analysis; (B) Fluorescence measurements of Alexa 647 (anti IgG) at different concentrations (1, 10,100 mg) conjugated to liposomes in
pH=7.4 or pH=8.5; (C) Fluorescence assessments of the conjugation yield of the anti IgG antibodies to the liposomes at pH=7.4 or pH=8.5; (D)
Recovery of liposomes after ultracentrifugation following antibody conjugation reaction at pH=7.4 or pH=8.5; (E, F) Western blot analysis for anti-
TfR or anti-IgG conjugated antibodies (E, upper blot) and antibody content in the supernatant (F, lower blot) after ultracentrifugation (pH=7.4).
doi:10.1371/journal.pone.0024202.g001
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studies involving Caco-2. TfR was stained with mouse anti-human
TfR following by Alexa 647 labeled goat anti-mouse IgG. TfR
expression and proliferation analysis was performed by flow
cytometry (LSR II, Becton, Dickinson Biosciences, ON, Canada).
Tf uptake by iron-starved Caco-2 cells
Low passage Caco-2 cells were cultured in DMEM containing
10% fetal bovine serum (FBS), 100 IU/ml of penicillin, 1% L-
glutamine, 1 mM sodium pyruvate and 1% non essential amino
acids. Cells were plated on m- slide 8 wells (Ibdi, Germany) at a
concentration of 3610
4 cells/well. After the addition of CRM the
plates were incubated for 24 h at 37uC. Fifty mg of Alexa 594-
labeled Tf (Tf-594, Invitrogen, CA, USA) was added and plates
incubated for additional 24 h. The cells were then rinsed twice
with PBS and Tf uptake was visualized by confocal microscopy
(Zeiss, Germany). Iron starvation was accomplished by the
addition of 10 mM DesferalH to the incubation medium. Non-
starved cells served in the control studies.
Uptake of the anti TfR- immunoliposomes by Caco-2
cells- confocal microscopy analysis
Iron-starved Caco-2 cells were cultured on m-slide 8 wells plates
(Ibdi, Germany) and incubated in the presence or absence of
proinflammatory cytokines (24 h, 37uC), followed by a 4 h
incubation (37uC) with 20 or100 ml of anti-TfR- immunolipo-
somes. After incubation the cells were washed twice with PBS and
imaged by confocal microscopy (Zeiss, Germany). Immunolipo-
somes carrying anti IgG antibodies served as a negative control.
Flow cytometry analyses for the uptake of Anti-TfR
liposomes by Caco-2 cells
CaCo-2 cells, pretreated with CRM and desferal for 24 hours
were incubation for 6 h with naked (no Ab.) liposomes, Lip-
aIgG100, lip-aTfR50, all fluorescently labeled formulations were
of equivalent florescence level. Flow cytometry analysis was
performed on LSR II instrument (Becton-Dickinson).
Uptake of the anti TfR- immunoliposomes by colon
mucosa
The colons specimens of either anesthetized DNBS-induced or
healthy rats were removed and rinsed with normal saline and
incubate (30 min, 37uC) with 2 mM of dithiothreitol to remove
the mucous lining which covers the epithelium. Everted sacs
(1 cm) were prepared and incubated (3 h, 37uC, while shaking) in
100 ml of the immunoliposomes, or liposomes without Ab
(Table 1), suspended in 1 ml of PBS. The sacs were then washed
twice with PBS and homogenized, on ice in 1 mL of acidic
isopropanol. The homogenates were centrifuged (25,000 g,
30 min, 4uC), and the clear supernatant was collected. After the
addition of a borate buffer (pH=9), fluorescence was measured
(excitation: 485 nm, emission:521 nm) and liposomes concentra-
tions were calculated with the aid of a 5 points calibration curve
which was made of increasing amounts of the liposomes in acidic
isopropanol.
Results
TfR expression was elevated in human specimens from
IBD patients and in the colonic epithelium of rats
induced with experimental colitis
To examine the relationship between epithelial inflammation in
the colon and TfR expression, we analyzed human colon biopsies
from Crohn’s disease patients. Specimens were taken from active
inflamed areas and compared to histological normal colonic
mucosa form patients with diseases other than IBD. Inflammation
was verified histologically by standard H&E staining (Figure 2A).
In 7 of 9 IBD patients elevated signal for TfR was obtained
compared to normal tissues (a total of 12 samples) (Figure 2B, 2C
and 2D). This signal may originate from the epithelial lining as
well as from the infiltrated immune cells or other cell types in the
specimen. Costaining with the specific epithelial marker E-
cadherin demonstrated that the vast majority of the TfR signal
emanates from the epithelial lining (Figure 2E), suggesting an
increased expression of TfR in the epithelial cells under conditions
of inflammation. Interestingly, while in the normal colonic mucosa
TfR expression was observed at the basolateral surface, in the
biopsies taken from active IBD patients TfR was clearly confined
also to the apical aspect of the mucosa (Figure 3).
To further examine whether TfR expression is affected by
inflammation conditions we established a DNBS-induced colitis in
rats. TfR expression was also measured in the colonic epithelium
of rats 4 days after experimental colitis induction (a period of time
which was required for the mucosa to recover from the local
damage caused by the ethanolic vehicle of the control group).
Inflammation was verified by H&E staining (Figure 4A) and
further characterized directly by measuring colon mucosa edema
ulceration and change in colon weight and length, and indirectly
by monitoring diarrhea, rat weight and hyperemia (Figure S1, A).
An elevation in mucosal TfR expression accompanied the DNBS
induced inflammation, compared with the sham treatment with
highest levels in the ulcerated regions of the mucosa (Figure 4B,
3C and 3D). This observation was verified by a Western blot of
total protein extraction from the inflamed and vehicle-treated rat
mucosa. As seen in Figure 4 (panels E and F), higher TfR
levels were observed in the former.
The elevated mucosal TfR level in the inflamed colons was
expected due to the inflammation-driven bleeding. This theoret-
ically should lead to the dwindling of iron depots, which signal via
RNA-binding iron regulatory proteins (IRP) signaling to increase
TfR translation [26,27]. To account for this possibility blood
samples of 3 vehicle-treated and 4 colitis-induced rats were
collected, sera was separated and tested, hematologically, for
anemia. Surprisingly, no difference between the two groups could
be observed for both red blood cells count and hemoglobin and
hematocrit levels (see Figures S1 and S2), suggesting a direct
impairment involved in the mucosal TfR elevated expression.
Proinflammatory cytokines promotes TfR expression in
Caco-2 cells
To better understand the involvement of induced inflammation
on TfR expression, we decided to explore, at the cellular level, the
role of proinflammatory mediators in TfR expression. The human
colon carcinoma Caco-2 cell line is a widely used model for colon
epithelium. Flow cytometry analysis of the Caco-2 cells incubated
with CRM revealed elevated cell surface TfR levels (Figure 5A,
5B). It has been shown that the exposure of Caco-2 cells to TNFa
(a proinflammatory cytokine, playing a major role in the
pathogenesis of IBD) increased iron ions uptake from the
incubation medium [28]. We therefore speculated that TNFa
was responsible, at least in part, for the CRM-induced increase in
TfR expression. Indeed incubation of the Caco-2 cells with
recombinant TNFa resulted in a similar increase in TfR
expression (Figure 5C). We conclude that proinflammatory
cytokines promote the cell surface expression of TfR in colon
epithelium.
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enhancement. For that purpose we imaged by confocal micros-
copy the uptake of fluorescent Tf by Caco-2 cells. Figure 6 shows
an enhanced Tf uptake caused by the presence of the CRM
cocktail, an effect which was even augmented when the cells were
deprived of iron by the addition of 100 mM of Desferal to the
incubation medium. Similar observation was obtained when the
study was repeated with IEC-6 cells (resemble normal, intestinal
Figure 2. Enhanced expression of TfR in inflamed colonic epithelium in humans. (A) Typical hematoxylin and eosin staining of human
biopsies taken from Crohn’s disease patients and patients with non-inflamed colonic mucosa.TfR immunostaining of transverse sections from human
biopsies taken from non-inflamed colonic mucosa (B) and from lesions of Crohn’s disease patients (C). Left panels (of B and C): nucleus staining (blue).
Right panels (of B and C): TfR staining (red). Magnification: 625; (D) Quantification of the fluorescence intensity (Image Pro Plus) in the specimens
taken from the Crohn’s patients (N=9) and non-inflamed (‘‘normal’’) patients (N=12) is shown on the left; (E) Anti-E-cadherin (left panel, green)
staining of inflamed tissue, staining of TfR (red) and nuclei (blue) (middle panel), merge (right panel).
doi:10.1371/journal.pone.0024202.g002
Figure 3. TfR is expressed at the apical aspect of the inflamed colonic epithelium in humans. Larger magnification (663) of (Figure 2B)
immunostained for TfR. Left: a transverse section from non-inflamed colonic mucosa. Right: a transverse section from a Crohn’s disease patients, the
basolateral membrane of the colon crypts is marked with white arrows, while the apical membrane is marked with yellow arrows.
doi:10.1371/journal.pone.0024202.g003
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assumption that iron uptake in the colon epithelium is affected by
local inflammation due to the increase in cell surface TfR.
Hyper proliferation was not involved in the cell-surface
TfR expression
In immune cells activation often triggers proliferation, which
necessitates higher uptake of iron. Therefore, we tested whether
cytokine-driven enhanced TfR expression was a consequence of
hyper proliferation, rather than a direct effect on TfR synthesis.
To address this, we monitored Caco-2 cell proliferation by the
carboxyfluorescein succinimidyl ester (CFSE) dilution assay. A
double staining of the cells in the presence or absence of human
TNFa, IL1b, IL-6, mix thereof or CRM, revealed a reduction in
the fraction of proliferating cells (Figure 7). Interestingly, TfR
levels were higher in the non-proliferating cells (CFSE high),
compared with the CFSE low population, indicating that the
proinflammatory cytokines had a net effect on the elevation in
cellular TfR expression, which was not related to their proliferation.
Cellular uptake of immunoliposomes is increased
compared with naked liposomes with and without
cytokine
Flow cytometry was also used for comparing the ability of the
immunoliposomes to direct themselves to CaCo-2 and IEC-6 cells
compared to the uptake of immunoliposomes bearing a nonspe-
cific Ab and with that of naked (no Ab) negatively charged lipo-
somes. Caco-2 cells were incubated with the various preparations
at equivalent fluorescence level. Figure 8 shows that anti-TfR
immunoliposomes accumulated to a higher level in Caco-2 cells.
Since the interaction between membrane TfR and anti-TfR
(either free or conjugated to the liposomal vehicle) should induce
endocytosis, it was expected that targeting the cellular TfR would
facilitate not only liposomal adherence, but also provoke their
Figure 4. TfR expression is elevated in the mucosa of DNBS induced rats. (A) Hematoxylin and eosin staining of rat colon specimens taken
from DNBS-induced rats 4 days after colitis induction and from healthy rat colonic mucosa.TfR immunostaining of transverse sections taken from the
mucosa of vehicle treated (B), DNBS-induced (C) and ulcerated region in the DNBS-induced (D) rats. Left panels: nucleus staining (blue). Right panels:
TfR staining (red). Magnification: 625; (E) immunoblot analysis of protein extracts (40 mg per lane) taken from the colon mucosa of sham treated
(‘‘healthy’’) or inflamed mucosa from DNBS-induced rats. Anti-TfR (95 kDa) was used for staining. (F) Blots quantification was performed by
densitometry and normalized to BiP (78 kDa). P-value ,0.05 was obtained by Mann-Whitney test.
doi:10.1371/journal.pone.0024202.g004
Figure 5. Proinflammatory cytokines increase TfR levels in Caco-2 cells. Flow cytometry analysis of Caco-2 cells following 48 h incubation
with LPS (negative control, A), CRM (B), or TNFa (C).
doi:10.1371/journal.pone.0024202.g005
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either fluorescently-labeled immunoliposomes or naked liposomes
with Caco-2 or IEC-6 cells at equivalent fluorescence level. The
incubation was conducted in the presence or absence of CRM.
Liposome uptake was assessed by confocal microscopy. When
uptake was compared, the anti-TfR liposomes entered the
endocytic pathway to higher efficiency than of the naked
liposomes (Figure 9A and B, left and middle panels).
Increase of the amount of liposomes was resulted in increased
uptake, indicating that the experiment was not performed under
saturation conditions (Figure 9A and B, right panel). Anti-TfR
liposomes were also found to be superior in their intracellular
uptake when compared to liposomes equipped with non-specific
antibody (Figure 9C).
Lastly, the targeting capability of the novel immunoliposomes
was tested in everted gut-sac preparations, taken from inflamed
colon of the DNBS induced rat and from vehicle treated control
rats. For that purpose 5 formulations were prepared: two
formulation of immunoliposomes bearing 5 or 50 mg anti-TfR
antibody, two negative control formulations, bearing 10 or 100 mg
non-specific antibody and naked liposomes (no antibody). We
observed that the anti-TfR immunoliposomes formulation ad-
hered significantly better (up to 4.5-fold) to the inflamed colon
epithelium compared with the three non specific formulations
(Figure 10A). This was in good agreement with the local TNFa
concentration in the mucosa (Figure 10B).We conclude that
immunoliposomes directed to the TfR may provide a means for
apical targeting to inflamed colon mucosa.
Discussion
In recent years, major improvements were achieved in the
management of IBD. The incorporation of immunosuppressive
agents as well as anti-TNFa antibodies improved IBD outcomes
and quality of life. However, toxicity and treatment failure
resulting in surgery are still major issues in the management of
IBD. Ferrying drugs directly to the colon (‘‘colonic delivery
systems’’) lacks the ability to target the inflamed mucosa and new
approaches that will allow mucosal accumulation of antiinflam-
matory drugs after oral or rectal administration are sought after
[9,29]. Employing a proteomic approach, in the search for suitable
mucosal targets, we identified recently that Tf accumulates at the
apical side of the inflamed gut mucosa [14]. This observation
impelled us to investigate whether Tf plays a physiological or
pathological role in regulating iron metabolism during colonic
inflammation. An obvious notion was to explore a possible linkage
between inflammation and local TfR expression. Moreover,
because TfR levels are elevated along with the local accumulation
of immune cells [16], we addressed the question whether similar
TfR increase, with potential medical merit, is observed in
epithelial cells, in addition to its systemic elevation.
TfR is encoded by two genes producing two types of the
receptor - TfR1 and TfR2. The affinity of the former to Tf is 25-
fold higher that the affinity of the latter. At the transcriptional level
TfR1 expression is controlled by the intracellular level of iron.
When the levels of iron drop, RNA- binding iron regulatory
proteins (IRPs) become active and bind to an IRE element in the
mRNA of TfR1. This IRP/IRE interaction stabilizes TfR1
mRNA and increases TfR1 production. Unlike TfR1, the
expression of TfR2 is not expressed ubiquitously and is not
influenced by intracellular iron levels [19,26,30]. The monoclonal
antibodies used in the course of this study were those against
TfR1.
In the present study, quantitative analysis of IF images of
human specimens from the colon epithelium of Crohn’s patients
and normal specimens showed that TfR expression was higher at
the membrane of colonocytes in IBD patients (Figures 2 and 3)
and in colitis-induced rats (Figure 4). Extracting the mucosal
proteins from the rat colons, followed by immunoblotting showed
a lesser difference in TfR levels (1.4-fold, Figure 5). The
observation that the relative expression of TfR in the mucosa of
the inflamed colon of the rat was lower than that of human
specimens compared with normal mucosa, suggeststhat the manner
by which inflammation is induced involves membrane trafficking of
TfR1, while the total intracellular pool of the receptor is less
affected. Interestingly, a 4-fold enrichment of cell surface TfR levels
was reported in malignant breast cells when compared to non-
neoplastic breast cells [19]. Thus, under harsh inflammatory
conditions TfR may serve as a therapeutic target similar to its use
in cancer. Because TfR is upregulated in proliferating cells it is not
surprising that both T and B lymphocytes express high levels of TfR
in DSS-induced mice [31]. Nonetheless, the regulation of TfR1
expression in macrophages is more complicated. While exposure of
macrophages to LPS and IFNc causes down regulation of surface
TfR1 [32], downstream signals, independent of IRP, enhance TfR
transcription and promotes its expression [16,33]. Only a small
number of studies addressed TfR expression in gut mucosal cells in
IBD. In a series of studies, Pallone et al showed that HLA-DR, 4F2
antigen and TfR are upregulated in IBD. Sixteen of 24 mucosal
specimens from colitis patients (compared with none of 7 normal
biopsies) were stained positively to TfR [15,34,35,36,37]. However,
because of technical limitations related to the year in which these
studies were conducted, the quality of the images and lack of
quantification precluded a clear conclusion to whether TfR expres-
sion is elevated on colonocytes themselves in colitis. Here, two
decades later, with improved imaging technology, we clearly show
that TfR is expressed on both the apical and the basolateral
membranes of the colonocytes in a manner directly correlated with
the severity of the disease (Figure 2). While in the non-inflamed
controls TfR was confined to the basolateral membrane, in the
biopsies taken from the colonic mucosa of Crohn’s patients TfR was
Figure 6. Proinflammatory cytokines promote Tf uptake by
CaCo-2 cells. The effect of CRM (lower panel) and iron starvation
(100 mM Desferal, right panel) on tagged (Alexa 594) Tf uptake by Caco-
2 cells as imaged by confocal microscopy (625).
doi:10.1371/journal.pone.0024202.g006
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contradiction to previous reports dealing with Madin-Darby canine
kidney(MDCK)cellsand Caco-2cells,inwhichTfRexpressionwas
40-fold higher in the basolateral than in the apical membranes. The
sorting signal of TfR to the basolateral surface was ascribed to
tyrosine motifs in its cytoplasmic tail [38,39,40]. A possible
explanation to the findings in our models is the injury caused by
the inflammation which may perturb the integrity of the tight
junctions separating the basolateral from the apical membranes,
allowing basolateral TfR to diffuse apically across the tight junc-
tions. Indeed, proinflammatory mediators, such as IL-13, IFNc and
TNFa have been shown to disrupt and dysfunction tight junctions
[41]. It remains to determine whether, in IBD, other typical
basolateral proteins relocalize towards the apical side of the cells,
indicating a general fault in cell polarity.
Another concern we had was that the increased level of TfR was
perhaps secondary to the development of anemia and not due to
direct effect on TfR regulation. Of the 9 specimens from Crohn’s
patients, at least four had overt clinical signs of anemia.
Nevertheless, no signs of anemia were observed in colonic mucosa
specimens from the colitis-induced rats, as indicated by various
hematological parameters, despite clear elevation in TfR expres-
sion (Figure S1 and S2). To further explore the inflammation-
mediated TfR regulation, we tested whether proinflammatory
Figure 7. Increased TfR expression in CaCo-2 cells is not due to enhanced proliferation. Flow cytometry analysis of CaCo-2 cells double
stained for CFSE dilution assay and TfR (mouse anti-human TfR stain), after incubation with the following inflammation mediators: TNFa, IL1b, IL-6, a
mixture of the three, or CRM from mouse source. (A) Dot plot of stained TfR levels and the proliferation marker, CFSE. Dividing cells are marked in red,
non-dividing cells are marked in blue; (B) Quantification of the dot plot shown in A; (C) TfR quantification in the dividing (red) and non-dividing (blue)
cell populations.
doi:10.1371/journal.pone.0024202.g007
Figure 8. Anti-TfR antibodies maintain functionality when
conjugated to the liposomes. Flow cytometry analysis of CaCo-2
cells pretreated with CRM and desferal for 24 hours following 6 h
incubation with fluorescently-labeled negative liposomes.
doi:10.1371/journal.pone.0024202.g008
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important proinflammatory cytokine in the pathogenesis of
Crohn’s disease as evident by the efficacy of anti-TNFa therapy
in the clinics [1,10,42]. Furthermore, it has been reported that the
exposure of Caco-2 cells to a mixture of TNFa, IL1b and IL-6
increased transferrin-iron uptake by 70%, inferring that proin-
flammatory cytokines are capable of modulating iron homeostasis
in intestinal epithelial cells [28]. For this reason we analyzed TfR
levels in Caco-2 cells subjected to cytokines treatment. We found
that TNFa was capable of increasing TfR levels in vitro in a
mechanism which does not involve hyper proliferation. In our
hands IL-6 and IL-1b did not affect TfR (Figures 5 and 7). It
would be interesting to test whether this effect of TNFa can be
subverted by anti-inflammatory cytokines. Regardless, our data
demonstrate a direct role of inflammation in the regulation of TfR
expression level.
Does apical TfR play a functional role in retrieving iron? One
third of IBD patients suffer from recurrent anemia due to iron
deficiency [30,43]. Physiologically, TfR is not involved in iron
absorption from the gut. However, because transferrin is accumu-
lated at the apical side of colonocytes in IBD, the simultaneous
enhancement in apical TfR levels could lead to reabsorbtion of the
leaked transferrin. If true, apical TfR could serve as a targeting
molecule in the design of specific drug delivery vehicles for the
treatment of IBD, owing to its location at the inflamed sites and the
possibility that it may trigger endocytosis upon ligation. TfR
targeting has been extensively studied in the context of cancer
therapy [26,27]. To this end TfR was targeted by virtue of its ligand
Tf, as well as by specific monoclonal antibodies or single chain
antibody fragments directed to its extracellular domain [27,44,45].
To explore the potentialof TfR as a means to direct drug vehicles to
theinflamedmucosawe preparednegativelychargedliposomes and
conjugated them with anti-TfR antibodies. Anti-TfR was favored
overTf dueto three reasons: first,endogenousTf which accumulate
in the inflamed mucosa [14] may competewithTf-bound liposomes
for TfR binding. In contrast, anti- TfR does not bind to the Tf
binding site and therefore less susceptible to direct competition.
Secondly, the pH of inflamed tissue becomes acidic. At pH lower
than 5, Tf acquires a positive charge which may form electrostatic
interactions with the negatively charged liposomes. The antibody is
most likely more resilient to changes in pH values. Lastly, at acidic
pH, typical to the colon lumen in IBD, Tf forms a stable complex
with TfR, which enable the release of iron and recycling Tf back to
the cell surface [26]. The acidic ambience in the inflamed colon
could potentially cause Tf to release the ferric ions and lose affinity
to the receptor.
Although not directly addressed in this study, we decided to
generate immunoliposomes as our model for drug delivery
vehicle owing to their capability to entrap a variety of drugs for
the topical treatment of IBD. In addition, if made at the right
size, they could adhere to the cellular membranes and deliver the
drug payload by endocytosis [46]. Since the immunoliposomes
are aimed at targeting mucosal tissues, the mucus barrier should
not be underestimated. To overcome this, PEG was used as a
spacer for the conjugation of the anti-TfR [47]. It has been
reported that PEG effectively minimizes adhesive interactions
between mucin mesh fibers and particles’ surface [48,49,50].
Preparation of the liposomes at acidic conditions, which should
theoretically increase their stability, did not improve the con-
jugation yield (Figure 1).
Figure 9. Cytokine treated CaCo-2 cells uptake better the immunoliposomes than naked liposomes. Representative images of confocal
scan microscopy of fluorescently-tagged immunoliposomes conjugated to anti-TfR Ab (center and right panels) or naked (no Ab) negative liposomes
(left panel) after 24 h of incubation with non stimulated (upper panels) or pre-incubated (lower panels) with CRM. Caco-2 cells are in panel A; IEC-6
cell are in panel B. Epifluorescence images following 10 h incubation of Lip-aIgG or Lip-aTfR in the presence or absence of CRM (C).
doi:10.1371/journal.pone.0024202.g009
TfR as a Target for Local Delivery to Inflammation
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24202Upon incubation with Caco-2 and IEC-6 cells, the immuno-
liposomes were internalized (Figures 8 and 9), indicating that
the liposomes were recognized by membrane TfR. Moreover, anti-
TfR facilitated the apical uptake to the rat inflamed mucosa by
more than 4-fold compared to their uptake by healthy mucosa
(Figures 10). TfR expression may rise globally due to development
of anemia or locally in healthy mucosal areas adjacent to the
inflamed regions, owing to leakage of proinflammatory cytokines
from the site of active inflammation to neighboring cells. If occurs, it
may allow preferential delivery of drugs to areas prone to exert
inflammation as the disease progresses. Obviously, because of these
reasons and because basal levels of TfR are expressed in the healthy
duodenum and proximal small intestine [27], liposomes equipped
withanti-TfR antibodyarenotsuitablefordrug deliveryviathe oral
route as is. However, once delivered to the distal organs of the
alimentary canal by either colonic delivery systems or by enema,
their homing tothesitesofinjurywillbe facilitated.Thisassumption
requires further verification.Inasmuch,we do notknow at this point
whether at an in vivo setting anti-TfR immunoliposomes will
penetrate the enterocytes by transcytosis, as suggested by Widera et
al [26], or remain confined to the apical site.
Overall, our findings delineate, for the first time that mucosal
TfR is directly regulated by proinflammatory cytokines and that
this regulation could be exploited for colon-specific delivery of
drugs, for the local treatment of IBD.
Supporting Information
Scheme S1 Preparation of the aTfR immunoliposomes.
The antibody solution was added to an aqueous dispersion of
negatively charged liposomes, bearing NHS-PEG-DSPE handle
and tagged with carboxyfluorescein (CF), right after their pre-
paration. Conjugation was accomplished by an overnight agitation
at room temperature, after which the reaction was stopped by the
addition of a TRIS buffer.
(TIF)
Figure S1 Characterization of DNBS induced colitis.
Scoring of the colon of saline treated or DNBS induced colitis. The
induced rats showed high score (total score of 4) as measured by
weight lost, diarrhea, colon weight, hyperemia, edema, ulcerated
areas and shorten of the colon length.
(TIF)
Figure S2 DNBS induced colitis do not develop anemia.
Blood count: blood count for healthy and inflamed rats: (a) white
blood cells count. (b) Red blood cells count. (c) Hemoglobin (d)
Hematocrit. (e) Mean corpuscular volume. (f) Mean Cell Hemoglobin.
Figure 10. Anti-TfR immunoliposomes adhere preferentially to inflamed mucosa. (A) Ex vivo adherence of two formulation bearing anti-
TfR antibody (‘‘Lip-aTfR5 ‘‘ and ‘‘lip-aTfR50’’ respectively), two negative control formulations, bearing non-specific antibody (‘‘Lip-aIgG10’’ and ‘‘Lip-
aIgG100’’ respectively) and naked liposomes (no antibody, ‘‘lip no Ab’’) to everted gut-sacs taken from DNBS-treated or vehicle treated rats. Shown
are the averages of 3 independent experiments 6 S.E.M. * P-value,0.05 was obtained by t- test. (B) TNFa levels analyzed by ELISA of inflamed and
non-inflamed homogenate tissue obtained from experimental induced colitis one or four days after colitis induction.
doi:10.1371/journal.pone.0024202.g010
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American medical Laboratories, AML, ISREAL, LTD. Healthy
(N=3), Inflammation (N=4).
(TIF)
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